In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

A Little Knowledge: The FDA's Public Approach to Safety

Executive Summary

The FDA's loudest critics on the safety issue have changed how FDA works-particularly in its far more public sharing of risk information. In a series of four interviews with FDA experts we explore the implications of these and other changes to the FDA's approach to safety. But one summary point: instead of trying to defend its record against an ever-increasing safety standard, the FDA--and some companies, too--are trying to teach consumers that all drugs have risks by informing them directly and frequently and thereby inoculate them against the more extreme requirements of the product-safety lobby.
Advertisement

Related Content

The Agency that Cries Wolf
Hurry Up and Wait: The Slowdown in Accelerated Approvals
The Vioxx Withdrawal: Can the Industry Avoid the Whirlpool?
The Outlook for Pharmacogenomics Testing in Primary Care
FDA Faces Mounting Pressure on Shortcut Approval Pathway
Forging a Path for Pharmacogenomics at the FDA

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

IV002558

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel